Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 39 of 59, showing 10 Applications out of 584 total, starting on record 381, ending on 390

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

381.

ECCT/19/03/01   Validation of syringe extension device
    Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures   
Principal Investigator(s)
1. Stephen Gwer
2. Aparna Ramanathan
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Kisumu County Hospital (Kisumu county)
3. God\'s Will Clinic (Kisumu county)
4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county)
 
01-08-2019 View

382.

ECCT/18/06/04   RANDOMIZED CONTROLLED TRIAL OF STEPPED UP VITAMIN A SUPPLEMENTATION DOSE ON IMMUNE RESPONSES AMONG INFANTS 6-12 MONTHS AT BUSIA LEVEL 4 HOSPITAL IN BUSIA COUNTY, KENYA
    BUSIA LEVEL IV HOSPITAL   
Principal Investigator(s)
1. BENARD OCHIENG WESONGA
Site(s) in Kenya
Busia Level IV Hospital
 
29-07-2019 View

383.

ECCT/19/05/03   SEARCH
    Supportive Care and Antibiotics for Severe Pneumonia among Hospitalised Children    
Principal Investigator(s)
1. Ambrose Agweyu
Site(s) in Kenya
1. Mama Lucy Kibaki Hospital (Nairobi City county)
2. Kiambu County Referral Hospital (Kiambu county)
3. Machakos County Referral Hospital (Machakos county)
4. Embu County Referral Hospital (Embu county)
5. Naivasha County Hospital (Nakuru county)
6. Bungoma County Referral Hospital (Bung\'oma county)
7. Busia County Referral Hospital (Busia county)
8. Kitale County Referral Hospital (Trans Nzoia county)
9. Kisumu East Hospital (Kisumu county)
10. Kakamega County Referral Hospital, Kenya (Kakamega county)
 
21-07-2019 View

384.

ECCT/19/04/01   A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants.
    Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants   
Principal Investigator(s)
1. Mainga Hamaluba
2. Kosgei Josphat
Site(s) in Kenya
1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county)
2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county)
 
08-07-2019 View

385.

ECCT/19/05/01   A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults
    A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
KAVI-ICR KNH SITE
 
08-07-2019 View

386.

ECCT/19/04/04   Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya
    Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya:two cluster-randomized controlled trials in pregnant women and their offspring and in 6-59 months old children comparing an agricultural intervention alone with a combined agricultural, nutrition and WASH intervention.       
Principal Investigator(s)
1. Rita Wegmuller
Site(s) in Kenya
1. Kakamega and Bungoma (Kakamega county)
 
05-07-2019 View

387.

ECCT/19/03/04   NIFTY
      Non-Inferiority Fractional-Doses Trial For Yellow Fever Vaccine         
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI Kilifi
 
21-06-2019 View

388.

ECCT/19/04/03   Phase III pediatric study with the L-PZQ ODTs
    An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®)   
Principal Investigator(s)
1. Maurice Reuben Odiere
Site(s) in Kenya
KEMRI-Centre for Global Health Research (CGHR)
 
18-06-2019 View

389.

ECCT/19/05/02   ETNA
    EVALUATION OF TECHNOLOGIES FOR NEONATES IN AFRICA   
Principal Investigator(s)
1. PROF WILLIAM MAINA MACHARIA
Site(s) in Kenya
1. AGA KHAN UNIVERSITY HOSPITAL (Nairobi City county)
2. PUMWANI MATERNITY HOSPITAL (Nairobi City county)
 
18-06-2019 View

390.

ECCT/19/06/01   EPI 003
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa.   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
1. Ahero clinical triasl unit (Kisumu county)
2. KEMI CDC (Siaya county)
 
17-06-2019 View